tradingkey.logo
tradingkey.logo
Search

Fulgent Genetics Inc

FLGT
Add to Watchlist
15.700USD
-0.490-3.03%
Close 05/15, 16:00ETQuotes delayed by 15 min
445.89MMarket Cap
LossP/E TTM

Fulgent Genetics Inc

15.700
-0.490-3.03%
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D

Today

-3.03%

5 Days

-1.63%

1 Month

-2.67%

6 Months

-46.05%

Year to Date

-40.24%

1 Year

-22.85%

TradingKey Stock Score of Fulgent Genetics Inc

Currency: USD Updated: 2026-05-15

Key Insights

Fulgent Genetics Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 28 out of 74 in the Healthcare Providers & Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 18.50.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Fulgent Genetics Inc's Score

Industry at a Glance

Industry Ranking
28 / 74
Overall Ranking
142 / 4482
Industry
Healthcare Providers & Services

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Fulgent Genetics Inc Highlights

StrengthsRisks
Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
Fairly Valued
The company’s latest PE is -6.55, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 18.21M shares, decreasing 7.22% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 2.23K shares of this stock.
Lower Market Activity
The company has less investor interest, with a 20-day turnover ratio of 0.74.

Analyst Rating

Based on 2 analysts
Buy
Current Rating
18.500
Target Price
+14.27%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Fulgent Genetics Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Fulgent Genetics Inc Info

Fulgent Genetics, Inc. is a technology-based company with a laboratory services business and a therapeutic development business. Its laboratory services business includes technical laboratory and testing services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. Its testing services include comprehensive anatomic pathology testing services, including gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology, and precision diagnostics testing services, including next-generation sequencing (NGS), tests for biopharma research and clinical tests for rare disease, hereditary cancer, reproductive health, and many other diseases.
Ticker SymbolFLGT
CompanyFulgent Genetics Inc
CEOHsieh (Ming)
Websitehttps://www.fulgentgenetics.com/
KeyAI